Indication

Lialda is indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC) and for the maintenance of remission of UC.

Important Safety Information

  • Lialda is contraindicated in patients with known hypersensitivity to salicylates or aminosalicylates or to any of the ingredients of Lialda.
  • Renal impairment, including minimal change nephropathy, acute and chronic interstitial nephritis, and, rarely, renal failure, has been reported with products such as Lialda that contain mesalamine or are converted to mesalamine. It is recommended that patients have an evaluation of renal function prior to initiating use of Lialda and periodically while on therapy. Exercise caution when using Lialda in patients with known renal dysfunction or a history of renal disease.

Read More Below

This site is intended for US health care professionals. Patient Site
For active, mild to moderate ulcerative colitis (UC)

Important Safety Information

Lialda is contraindicated in patients with known hypersensitivity to salicylates or aminosalicylates or to any of the ingredients of Lialda. See Important Safety Information

Lialda® (mesalamine): #1 Prescribed 5-ASA Among Gastroenterologists1

We’re Sorry

The page you are looking for cannot be found on this site. If you typed an address into your browser’s address bar, please check to see that it is spelled correctly. If it is, the page may have been removed from the site or had its name changed. It may also be temporarily unavailable.

Try looking at the site map for a complete list of the pages currently available on this site.

Back to top Back to top